Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes

    Question

    Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes

    Direct answer

    Vaxcyte finalized terms on a concurrent $1 billion capital raise split equally between equity and low-coupon convertible debt. The equity portion placed 7.4 million shares at $64.00 each, while the debt tranche placed $500 million in senior convertible notes due 2032 at a 1.50% coupon. The structure minimizes immediate dilution compared to a pure equity offering while locking in long-dated debt financing below current high-yield benchmark rates.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1b-concurrent-public-offering-of-equity-and-convertible-notes-efe4bd

    EQUITY
    Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes
    Vaxcyte finalized terms on a concurrent $1 billion capital raise split equally between equity and low-coupon convertible debt. The equity portion placed 7.4 million shares at $64.00 each, while the debt tranche placed $500 million in senior convertible notes due 2032 at a 1.50% coupon. The structure minimizes immediate dilution compared to a pure equity offering while locking in long-dated debt financing below current high-yield benchmark rates.
    PCVX
    Impact
    73
    OCT 7
    SIG
    92%
    PCVX
    Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes
    Vaxcyte finalized terms on a concurrent $1 billion capital raise split equally between equity and low-coupon convertible debt. The equity portion placed 7.4 million shares at $64.00 each, while the debt tranche placed $500 million in senior convertible notes due 2032 at a 1.50% coupon. The structure minimizes immediate dilution compared to a pure equity offering while locking in long-dated debt financing below current high-yield benchmark rates.
    → Supply of 7.4 million new shares at $64.00 per share expands PCVX equity float and caps short-term upside while $500 million in 1.50% convertible notes lowers weighted average cost of debt.
    Impact
    Vaxcyte finalized terms on a concurrent $1 billion capital raise split equally between equity and low-coupon convertible debt. The equity portion placed 7.4 million shares at $64.00 each, while the debt tranche placed $500 million in senior convertible notes due 2032 at a 1.50% coupon. The structure minimizes immediate dilution compared to a pure equity offering while locking in long-dated debt financing below current high-yield benchmark rates.
    Affected
    PCVX
    Transmission
    Supply of 7.4 million new shares at $64.00 per share expands PCVX equity float and caps short-term upside while $500 million in 1.50% convertible notes lowers weighted average cost of debt.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity float expansion at fixed discount to marketMixedintradayVaxcyte priced 7.4 million common shares at $64.00 and $500M in 1.50% convertible notes.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month